Top

Journal of Radiation Oncology

Published in:

01-09-2017 | Original Research

Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic adenocarcinoma

Authors: Raj Singh, Hayden Ansinelli, Sanjeev Sharma

Published in: Journal of Radiation Oncology | Issue 3/2017

Abstract

Objectives

The purpose of this study was to report on progression-free survival (PFS), overall survival (OS), and related toxicities following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic cancer (PCa).

Methods

The RSSearch® Patient Registry was screened for PCa patients treated with SBRT. The relationship between PFS, OS, and potential prognostic factors were evaluated using the Kaplan-Meier method and continuous log-rank analysis, and the correlation between treatment planning and toxicity incidence was examined by logistic regression.

Results

Sixty patients met inclusion criteria. Twenty-three patients (38.33%) had received adjuvant gemcitabine. Following SBRT, median PFS was 6.07 months (range: 2.33 - 34.4 months) and median OS was 8.55 months (range: 2.66 - 78.53 months). Single-fraction SBRT trended towards poorer median PFS (5.13 vs. 6.76 months; p = 0.0122) with no significant difference in median OS (10.3 vs. 7.17 months; p = 0.8896). PCas located in the head had a significantly higher median OS (9.58 months) as compared to those in the body (5.66 months; p = 0.0376). Adjuvant gemcitabine did not result in superior PFS (5.12 vs. 6.35 months; p = 0.52) or OS (8.67 vs. 7.07 months; p = 0.6010). Eight (13.3%) and six (10%) patients reported acute and late toxicities, respectively, that were all Grade 1 or 2. Single-fraction SBRT was associated with an increased risk of toxicity incidence (5/9 patients vs. 3/51 patients; p = 0.001).

Conclusion

SBRT was well-tolerated by PCa patients with fractionated SBRT trending towards superior PFS and less toxicity as compared to single-fraction SBRT.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. doi:10.3322/caac.21332 CrossRefPubMed

Willett CG, Czito BG, Bendell JC, Ryan DP (2005) Locally advanced pancreatic cancer. J Clin Oncol 23(20):4538–4544. doi:10.1200/JCO.2005.23.911 CrossRefPubMed

Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91(5):586–594. doi:10.1002/bjs.4484 CrossRefPubMed

Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, Gibbs J, Kuvshinoff B, Wilding G, Warren G, Yang GY (2012) Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol 3(4):326–334. doi:10.3978/j.issn.2078-6891.2012.029 PubMedPubMedCentral

Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371(22):2140–2141. doi:10.1056/NEJMc1412266 PubMed

Oh SY, Edwards A, Mandelson MT, Lin B, Dorer R, Helton WS, Kozarek RA, Picozzi VJ (2015) Rare long-term survivors of pancreatic adenocarcinoma without curative resection. World J Gastroenterol 21(48):13574–13581. doi:10.3748/wjg.v21.i48.13574 CrossRefPubMedPubMedCentral

Lominska CE, Unger K, Nasr NM, Haddad N, Gagnon G (2012) Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas. Radiat Oncol 7:74. doi:10.1186/1748-717X-7-74 CrossRefPubMedPubMedCentral

Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC (2009) Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115(3):665–672. doi:10.1002/cncr.24059 CrossRefPubMed

Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72(3):678–686. doi:10.1016/j.ijrobp.2008.01.051 CrossRefPubMed

10.

Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 3(3):373–378. doi:10.1200/JCO.1985.3.3.373 CrossRefPubMed

11.

Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C (2010) Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 78(3):735–742. doi:10.1016/j.ijrobp.2009.08.046 CrossRefPubMed

12.

Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48(8):1705–1710CrossRefPubMed

13.

Goyal K, Einstein D, Ibarra RA, Yao M, Kunos C, Ellis R, Brindle J, Singh D, Hardacre J, Zhang Y, Fabians J, Funkhouser G, Machtay M, Sanabria JR (2012) Stereotactic body radiation therapy for nonresectable tumors of the pancreas. J Surg Res 174(2):319–325. doi:10.1016/j.jss.2011.07.044 CrossRefPubMed

14.

Lominska CE, Nasr NM, Silver NL, Gagnon GJ (2008) Salvage stereotactic radiosurgery for locally recurrent previously irradiated pancreatic cancer. Int J Radiat Oncol Biol Phys 72(1):S276–S277CrossRef

15.

Davis JN, Medbery C 3rd, Sharma S, Danish A, Mahadevan A (2013) The RSSearch registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. Radiat Oncol 8:275. doi:10.1186/1748-717X-8-275 CrossRefPubMedPubMedCentral

16.

Singh R, Davis J, Sharma S (2016) Stereotactic radiosurgery for trigeminal neuralgia: a retrospective multi-institutional examination of treatment outcomes. Cureus 8(4):e554. doi:10.7759/cureus.554 PubMedPubMedCentral

17.

Davis JN, Medbery C, Sharma S, Pablo J, Kimsey F, Perry D, Muacevic A, Mahadevan A (2015) Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch((R)) patient registry. Radiat Oncol 10:113. doi:10.1186/s13014-015-0417-5 CrossRefPubMedPubMedCentral

18.

Didolkar MS, Coleman CW, Brnener MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinotwitz S (2010) Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma: results of first 85 patients. J Gastrointest Surg 14(10):1547–1559. doi:10.1007/s11605-010-1323-7 CrossRefPubMed

19.

Mahadevan A, Floyd S, Wong E, Jeyapalan S, Groff M, Kasper E (2011) Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases. Int J Radiat Oncol Biol Phys 81(5):1500–1505. doi:10.1016/j.ijrobp.2010.08.012 CrossRefPubMed

20.

Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ (2008) Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 26(6):942–947. doi:10.1200/JCO.2007.13.9014 CrossRefPubMed

21.

Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68(3):801–808. doi:10.1016/j.ijrobp.2006.12.053 CrossRefPubMed

22.

Min YJ, Joo KR, Park NH, Yun TK, Nah YW, Nam CW, Park JH (2002) Gemcitabine therapy in patients with advanced pancreatic cancer. Korean J Intern Med 17(4):259–262CrossRefPubMedPubMedCentral

23.

Rwigema JC, Parikh SD, Heron DE, Howell M, Zeh H, Moser AJ, Bahary N, Quinn A, Burton SA (2011) Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 34(1):63–69. doi:10.1097/COC.0b013e3181d270b4 CrossRefPubMed

24.

Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H (2005) Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76(1):48–53. doi:10.1016/j.radonc.2004.12.022 CrossRefPubMed

25.

Nimura Y, Hattori T, Miura K, Nakajima N, Hibi M (1976) Experience of Appleby’s operation for advanced carcinoma of the pancreatic body and tail. Shujutsu 30:885–889

26.

Parlak C, Topkan E, Onal C, Reyhan M, Selek U (2012) Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiat Oncol 7:37. doi:10.1186/1748-717X-7-37 CrossRefPubMedPubMedCentral

27.

Tas F, Sen F, Keskin S, Kilic L, Yildiz I (2013) Prognostic factors in metastatic pancreatic cancer: older patients are associated with reduced overall survival. Mol Clin Oncol 1(4):788–792. doi:10.3892/mco.2013.131 PubMedPubMedCentral

28.

Su TS, Liang P, Lu HZ, Liang JN, Liu JM, Zhou Y, Gao YC, Tang MY (2015) Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer. World J Gastroenterol 21(26):8156–8162. doi:10.3748/wjg.v21.i26.8156 CrossRefPubMedPubMedCentral

Title: Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic adenocarcinoma
Authors: Raj Singh
Hayden Ansinelli
Sanjeev Sharma
Publication date: 01-09-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 3/2017
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-017-0313-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2017

Early-stage non-small cell lung cancer in the USA: patterns of care and survival among elderly patients at least 80 years old

Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy

A pilot study to determine if the use of a virtual reality education module reduces anxiety and increases comprehension in patients receiving radiation therapy

Radiographic predictors of response to endoluminal brachytherapy for the treatment of rectal cancer

Radiation therapy for localized malignant pleural mesothelioma: a propensity score-matched analysis of the National Cancer Data Base

Radiation injury to cardiac arteries and myocardium is reduced by soy isoflavones

Keynote webinar | Spotlight on antibody–drug conjugates in cancer